Lilly sues six US retatrutide sellers and asks platforms and payment firms to cut them off

Eli Lilly said on Aug. 12, 2026 that it had filed six more lawsuits against U.S. sellers of black-market retatrutide, and it publicly asked the companies those sellers rely on — social networks, shopping platforms, card networks, payment processors and shipping firms — to cut off the trade ^[2].

Retatrutide is still an investigational molecule. Lilly is studying it in Phase 3 trials for obesity, type 2 diabetes and related conditions, and no regulatory agency anywhere has approved a medicine containing it ^[2]. Because of that, it cannot be sold to consumers, and the FDA has said it also cannot lawfully be compounded ^[2]. STAT, reporting the same week, described the company's move as aimed at a booming black market ^[1].

What the filings target

The new cases were brought in federal courts in California and Texas against Aesthetic Envy Cosmetic Centers LLC (N.D. Cal.), Astra LLC, which does business as Astra Peptides (W.D. Tex.), Legendary Peptides, LLC (E.D. Tex.), Striker Pharmacy, LLC (S.D. Tex.), Texas Peptides Inc. (W.D. Tex.) and Lone Star Peptide Co. (S.D. Tex.) ^[2].

Lilly said the defendants include compounding pharmacies, medical spas and internet sellers that describe their products as "research-use only" even though the products are meant for people ^[2]. The company said it has flagged more than 200 people and businesses to the FDA, the Justice Department, state attorneys general, police and professional licensing boards, and that it has reported more than 14,000 websites, ads, posts and product listings across more than 100 countries, with some of that content still online ^[2].

"What is being sold on the black market is not a medicine," Lilly chief medical officer David A. Hyman said in the announcement ^[2].

Why it matters for patients

Retatrutide is not one of the GLP-1 medicines that have been through regulatory review. Semaglutide is sold as Ozempic, Wegovy and Rybelsus; tirzepatide as Mounjaro and Zepbound. Retatrutide has no approved form in any country ^[2].

A vial or pen sold as "reta" online, at a med spa or through a wellness clinic has therefore not been checked by any regulator for what is in it, how strong it is or whether it is sterile. Lilly says such products are often made by unregulated manufacturers abroad, and that authorities in several countries have raided production sites, seized shipments and arrested people ^[2].

If platforms and payment firms act on Lilly's request, buyers would have fewer places to find the drug and fewer ways to pay for it. None of those companies has publicly agreed to do so ^[2].

Several things remain undisclosed. Lilly has not said how much money it seeks in the six cases, whether any defendant has answered, whether testing found the labeled ingredient in any product, or when courts might schedule hearings ^[2].

People who come across listings for illegal retatrutide can report them to law enforcement, drug and pharmacy regulators, or Lilly's Answers Center at 1-800-LillyRx, the company said ^[2].

What happens next

The six suits are pending in federal district courts in California and Texas ^[2]. Lilly said it will keep working with regulators, police and customs agencies outside the United States ^[2]. Retatrutide remains available only to participants in clinical trials ^[2].